[Biosynthetic growth hormone in the treatment of low stature in Turner syndrome].
Fifteen patients with Turner's syndrome with ages between 6.8 to 13.2 years were treated with biosynthetic growth hormone due to their low height. Twelve of them had a 45XO karyotype and three were mosaics; none had a Y line. They started with 0.7 IU/kg/week which were increased to 1.0 IU/kg/week if no height gain was observed during three months. The 15 patients have completed one year of treatment, 8 of them for two years. The height velocity increased significantly (p < 0.001) from 0.24 +/- 0.10 cm/month before treatment (mean +/- SD) to 0.48 +/- 0.09 in the first 12 months of treatment (height increased from 119.1 +/- 8.79 to 124.9 +/- 8.70). In the eight cases who have reached 24 months of treatment, the height velocity increased from 0.27 +/- 0.07 cm/month to 0.47 +/- 0.09 and 0.54 +/- 0.10 at 12 and 24 months respectively (p < 0.001 and p < 0.01 versus the pretreatment gain); height increased from 116.8 +/- 7.0 cm to 122.0 +/- 7.45 and 129.0 +/- 7.18. We found no adverse effects in the patients. It is concluded that the biosynthetic growth hormone treatment in Turner's syndrome can improve low height.
Mendoza-Morfín
F
F
Departamento Clínico de Endocrinología Pediátrica, Hospital General, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, México, D.F.
Montero-González
P
P
Cárdenas-Tirado
H
H
Bravo-Ríos
L E
LE
D000293:Adolescent; D001827:Body Height / Q000187:drug effects; D002648:Child; D004392:Dwarfism / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D013006:Growth Hormone / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use*; D006801:Humans; D007621:Karyotyping; D009030:Mosaicism; D011994:Recombinant Proteins / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use*; D014424:Turner Syndrome / Q000150:complications* / Q000235:genetics
D011994:Recombinant Proteins; D013006:Growth Hormone